GGHC
ADMS

Gilder Gagnon Howe & Co’s Adamas Pharmaceuticals ADMS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-541,421
Closed -$7.83M – 288
2016
Q1 		$7.83M Buy
+541,421
New +$9.12M 0.15% 92

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Gilder Gagnon Howe & Co's ADMS Position: Q2 2016 in Review

Gilder Gagnon Howe & Co sold out of Adamas Pharmaceuticals (ADMS) in Q2 2016, closing a stake of 541,421 shares — an estimated $7.83M sold.

Gilder Gagnon Howe & Co first reported a position in ADMS in Q1 2016 and held it in 1 quarter. The position peaked at $7.83M in Q1 2016. 84 funds tracked by Wall St. Rank hold ADMS as of Q2 2016.

  • Gilder Gagnon Howe & Co reported no remaining Adamas Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 541,421 Adamas Pharmaceuticals shares in Q2 2016, an estimated $7.83M.
  • Gilder Gagnon Howe & Co first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Adamas Pharmaceuticals position peaked at $7.83M in Q1 2016.
  • 84 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2016, filed 1 Aug 2016.